Core Viewpoint - China is increasingly becoming a research and development (R&D) hub for multinational companies, reflecting a shift from being merely a manufacturing base to a center for innovation and R&D investment [1] Group 1: Foreign Investment in R&D - From January to August 2025, 42,435 new foreign-invested enterprises were established in China, marking a 14.8% year-on-year increase, indicating sustained enthusiasm for foreign investment and an optimized investment structure [2] - Since 2013, R&D expenditure of foreign-funded industrial enterprises in China has increased by over 86.5%, with Shanghai surpassing 600 foreign R&D centers and Beijing's number doubling compared to the previous year [2] - Henkel has made significant investments in R&D projects in China, including the opening of its largest Asian R&D center in January 2024 and a new innovation experience center in September 2024 with a total investment of approximately 500 million yuan [2] Group 2: Pharmaceutical Sector Investments - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in Beijing, making it one of two such centers in China, with plans to launch 20 global innovative drugs by 2030 [3] - Schneider Electric has established multiple R&D centers in China, with an annual compound growth rate of over 18% in R&D investment since 2019, emphasizing the importance of local innovation [3] Group 3: Optimized Innovation Ecosystem - The increasing enthusiasm for foreign R&D investment in China is attributed to the country's large market size, favorable policy environment, and robust innovation ecosystem [4] - China has created a unique innovation advantage with a demand-driven, industry-supported, and talent-driven ecosystem, aligning well with the technological expertise of companies like Schneider Electric [4] Group 4: Global Business Impact - Bayer's new innovation cooperation center in Shanghai reflects a deepening R&D presence in China, supported by a stable policy environment that encourages innovation in the pharmaceutical and health sectors [5] - The rapid development of new technologies such as artificial intelligence and green energy in China presents significant market opportunities for multinational companies [6] - Cross-border innovations developed in China are increasingly serving global markets, with Bayer's innovative products from China accounting for 15% of its global innovation output as of 2023 [7] Group 5: Local Market Adaptation - Companies are recognizing the need to adapt to the unique characteristics of the Chinese market to maintain competitiveness, with local R&D enhancing supply chain flexibility and accelerating innovation [7][8] - Schneider Electric's environmentally friendly products developed in China are being promoted globally, showcasing the potential for "China's creation" to benefit worldwide markets [8]
创新生态持续优化 中国成为跨国企业研发热土
Jing Ji Ri Bao·2025-10-25 05:00